MRI contrast developer Epix Pharmaceuticals has received approval from the Australian Therapeutic Goods Administration (TGA) to market its Vasovist blood-pool imaging agent.
Vasovist is indicated for contrast-enhanced MR angiography for visualization of abdominal or limb vessels in patients with suspected or known vascular disease. The agent is now available in 27 countries, according to the Lexington, MA-based firm.
By AuntMinnie.com staff writers
September 20, 2006
Related Reading
Epix regains Nasdaq symbol, September 15, 2006
FDA rejects Epix appeal, August 28, 2006
Epix, Predix complete merger, August 17, 2006
Epix, Predix shareholders approve merger, August 15, 2006
Epix nears Australia approval for Vasovist, August 14, 2006
Copyright © 2006 AuntMinnie.com
